Current Liabilities decreased faster than Acrivon Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Acrivon Therapeutics Inc 's Quick Ratio to 104.48 a new company high.

Within Major Pharmaceutical Preparations industry 2 other companies have achieved higher Quick Ratio than Acrivon Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 42, from total ranking in the first quarter 2026 at 366.

Explain Quick Ratio?
How much Cash & cash equivalents ACRV�s has?
What are ACRV�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ACRV Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-93.59 %	-18.42 %	-9 %	0.49 %	19.03 %
Y / Y Cash & cash equivalent Change	-34.54 %	-34.68 %	-33.93 %	-31.05 %	-23.88 %
Quick Ratio MRQ	104.48	8.84	7.57	8.68	10.23
ACRV's Total Ranking	# 42	# 366	# 416	# 349	# 252
Seq. Current Liabilities Change	-92.21 %	-29.43 %	5.19 %	10.87 %	-0.88 %
Seq. Cash & cash equivalent Change	-7.96 %	-17.58 %	-8.26 %	-5.94 %	-8.16 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 3
Healthcare Sector	# 4
Overall Market	# 42

Quick Ratio Statistics
High	Average	Low
104.48	19.63	7.57
(Jun 30 2026)		(Dec 31 2025)

Financial Statements
Acrivon Therapeutics Inc 's Current Liabilities	$ 1 Millions	Visit ACRV's Balance sheet
Acrivon Therapeutics Inc 's Cash & cash equivalent	$ 90 Millions	Visit ACRV's Balance sheet
Source of ACRV's Sales		Visit ACRV's Sales by Geography

Cumulative Acrivon Therapeutics Inc 's Quick Ratio

ACRV's Quick Ratio for the trailling 12 Months

ACRV Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-28.03 %	-3.21 %	9.89 %	21.96 %	37.48 %
Y / Y Cash & cash equivalent TTM Growth	-33.4 %	-30.71 %	-18.64 %	-1.59 %	16.77 %
Quick Ratio TTM	10.26	8.78	9.3	10.08	11.08
Total Ranking TTM	# 3736	# 2526	# 2574	# 2700	# 2357
Seq. Current Liabilities TTM Growth	-22.84 %	-4.34 %	-2.62 %	0.12 %	3.78 %
Seq. Cash & cash equivalent TTM Growth	-9.83 %	-9.7 %	-10.22 %	-8.9 %	-6.18 %

Quick ratio ranking by company, industry and sector >> Back to ACRV Financial Strength Comparisons >> Go to Compare ACRV Quick Ratio to its Competitors

News about Acrivon Therapeutics Inc Quick Ratio

Unlocking Precision Oncology: Acrivon Therapeutics Secures $130 Million in Private Placement Financing

Acrivon Therapeutics, a pioneering biopharmaceutical company, has made significant strides in the field of precision oncology. With its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), the company is revolutionizing cancer treatment by developing targeted medicines tailored to individual patients. In a recent announcement, Acrivon Therapeutics disclosed a private placement financing round, raising an impressive $130 million from existing and new accredited investors. This financial boost will undoubtedly accelerate the company s quest to deliver highly effective oncological therapies.
The Power of Precision Oncology:
Cancer treatment has come a long way, and precision oncology represents the most promising frontier in this field. By identifying specific biomarkers and utilizing sophisticated analytics, researchers are now able to design medicines that target cancer cells with unparalleled precision. Acrivon Therapeutics is at the forefront of this transformative approach, hinging its drug development on the ability to match therapies to patients whose tumors are predicted to be sensitive to each specific medicine. This personalized treatment approach reduces adverse effects, increases efficacy, and paves the way for improved patient outcomes.

On the trailing twelve months basis Current Liabilities decreased faster than Acrivon Therapeutics Inc 's average Cash & cash equivalent, this led to increase in in Acrivon Therapeutics Inc 's Quick Ratio to 10.26, above ACRV average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 428 other companies have achieved higher Quick Ratio than Acrivon Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2526 to 3736.

Explain Quick Ratio?
How much Cash & cash equivalents ACRV�s has?
What are ACRV�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 429
Healthcare Sector	# 873
Within the Market	# 3736

trailing twelve months Quick Ratio Statistics
High	Average	Low
8.78	3.66	2.64
(Mar 31 2023)		(Sep 30 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Mira Pharmaceuticals Inc	198.75	$ 8.113 Millions	$ 0.041 Millions
Veradermics Inc	139.85	$ 1,635.362 Millions	$ 11.694 Millions
Enliven Therapeutics Inc	116.86	$ 1,654.850 Millions	$ 14.161 Millions
Acrivon Therapeutics Inc	104.48	$ 89.959 Millions	$ 0.861 Millions
Arca Biopharma Inc	87.05	$ 2,225.581 Millions	$ 25.566 Millions
Tango Therapeutics Inc	82.19	$ 1,668.432 Millions	$ 20.299 Millions
Contineum Therapeutics Inc	70.25	$ 458.440 Millions	$ 6.526 Millions
Sagimet Biosciences inc	61.23	$ 331.832 Millions	$ 5.419 Millions
Avalyn Pharma Inc	49.93	$ 539.733 Millions	$ 10.809 Millions
Pasithea Therapeutics Corp	49.76	$ 91.464 Millions	$ 1.838 Millions
Disc Medicine Inc	44.03	$ 1,336.770 Millions	$ 30.360 Millions
Trevi Therapeutics Inc	36.50	$ 318.870 Millions	$ 8.736 Millions
Design Therapeutics Inc	35.76	$ 401.889 Millions	$ 11.240 Millions
Mineralys Therapeutics Inc	34.87	$ 673.704 Millions	$ 19.319 Millions
Praxis Precision Medicines Inc	34.32	$ 1,683.790 Millions	$ 49.058 Millions
Agios Pharmaceuticals Inc	33.94	$ 2,383.112 Millions	$ 70.217 Millions
Mbx Biosciences Inc	33.10	$ 783.099 Millions	$ 23.660 Millions
Xbiotech Inc	32.67	$ 109.528 Millions	$ 3.353 Millions
Avalo Therapeutics Inc	31.89	$ 787.143 Millions	$ 24.682 Millions
Fulcrum Therapeutics Inc	30.96	$ 318.840 Millions	$ 10.298 Millions
Climb Bio Inc	30.86	$ 183.123 Millions	$ 5.934 Millions
Indaptus Therapeutics Inc	29.61	$ 15.554 Millions	$ 0.525 Millions
Crinetics Pharmaceuticals Inc	29.41	$ 2,350.275 Millions	$ 79.915 Millions
Spyre Therapeutics Inc	28.48	$ 1,100.000 Millions	$ 38.620 Millions
Curanex Pharmaceuticals Inc	28.17	$ 2.938 Millions	$ 0.104 Millions
Onkure Therapeutics Inc	28.04	$ 186.284 Millions	$ 6.643 Millions
Ligand Pharmaceuticals Incorporated	27.33	$ 1,277.438 Millions	$ 46.736 Millions
Shattuck Labs Inc	26.94	$ 208.300 Millions	$ 7.731 Millions
Cryoport inc	26.87	$ 785.860 Millions	$ 29.244 Millions
Roivant Sciences Ltd	26.82	$ 7,607.076 Millions	$ 283.603 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.